Lina Felipez
University of Chicago
Internal medicinePhenotypeSurgeryHeterozygote advantagePharmacogenomicsIntensive care medicineAlleleAdverse effectImmunologyColitisAzathioprineLiver diseaseInfliximabErythrocyte sedimentation rateInflammatory bowel diseaseCytokineDiscontinuationPrednisoneDiseaseConcomitantThalidomideHermansky–Pudlak syndromeDrugSingle CenterAdalimumabTherapeutic drug monitoringAlpha 1-antitrypsin deficiencySevere colitisDrug reactionMedical therapyIn patientPatient characteristicsAnti tumor necrosis factor alphaAnti tnf alphaSerologyPharmacotherapyMutationLiver function testsMonoclonal antibodyMalnutritionHistologyMedicineMissense mutationGastroenterology
8Publications
3H-index
48Citations
Publications 8
Newest
Source
Source
#1Lina Felipez (U of C: University of Chicago)H-Index: 3
#2Ranjana GokhaleH-Index: 10
Last. Barbara S. KirschnerH-Index: 46
view all 4 authors...
OBJECTIVE: The aim of the study was to evaluate thalidomide as rescue therapy for pediatric patients with severe refractory Crohn disease (CD) who failed to respond to antitumor necrosis factor (TNF) biologic agents. PATIENTS AND METHODS: A computerized database was used to identify children with CD who had failed conventional immunosuppression therapy and received thalidomide rescue therapy. Twelve patients, mean age at diagnosis 10 years, were identified. Eight children had disease localized t...
32 CitationsSource
#1Lina FelipezH-Index: 3
#2Ranjana GokhaleH-Index: 10
Last. Barbara S. KirschnerH-Index: 46
view all 5 authors...
2010, we identified pediatric patients who had pelvic MRI for perianal fistula prior to starting anti-TNF alpha therapy. RESULTS: We identified 15 patients (11 male; mean age 14 years; range 8-19 years) who had an MRI identifying a perianal fistula and subsequently received infliximab (5-10mg/kg). Subjects who failed treatment with infliximab or developed an adverse reaction changed to adalimumab or certolizumab. Nine patients had perianal fistulas, 3 had combined perianal/peritoneal fistulas, 1...
Source
#1Lina Felipez (U of C: University of Chicago)H-Index: 3
#2Ranjana GokhaleH-Index: 10
Last. Stefano GuandaliniH-Index: 59
view all 3 authors...
8 CitationsSource
#1Lina Felipez (U of C: University of Chicago)H-Index: 3
#2Timothy Sentongo (U of C: University of Chicago)H-Index: 15
Good clinical care extends beyond mere diagnosis and treatment of disease to appreciation that nutrient deficiencies can be the price of effective drug therapy. The major risk factors for developing drug-induced nutrient deficiencies are lack of awareness by the prescribing physician and long duration of drug therapy. The field of pharmacogenomics has potential to improve clinical care by detecting patients at risk for complications from drug therapy. Further improvements in patient safety rely ...
9 CitationsSource
Source
#1Lina FelipezH-Index: 3
#2Timothy SentongoH-Index: 15